Clinical Trials Logo

CNS Malignancies clinical trials

View clinical trials related to CNS Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT06466798 Not yet recruiting - Clinical trials for Recurrent Medulloblastoma

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety, toxicity, and antitumor activity of fourth ventricular infusions of nivolumab plus 5-azacytidine for recurrent ependymoma and nivolumab plus methotrexate for recurrent medulloblastoma and other CNS malignancies. Additionally, the study will explore immunologic responses to nivolumab. The hypothesis is that local administration of nivolumab, an immune checkpoint inhibitor, is safe and will lead to even more robust treatment responses when administered following 5-azacytidine in patients with recurrent ependymoma or methotrexate in patients with medulloblastoma or other CNS tumors.

NCT ID: NCT02564198 Completed - Clinical trials for Pediatric Solid Tumor

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Start date: December 11, 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

NCT ID: NCT00756340 Completed - CNS Malignancies Clinical Trials

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The main goals of this Phase I study are to learn about the side effects that may occur when everolimus and bevacizumab are given to children and young adults and to find the highest doses of these drugs that can be given together without causing severe side effects. Bevacizumab will be given into the vein (IV) over 30-90 minutes every two weeks and everolimus tablets will be given daily by mouth. A cycle of therapy will be four weeks.